A Review of the Use of Chemoprotectants in Cancer Chemotherapy

This publication has 53 references indexed in Scilit:

• The current status of toxicity protectants in cancer therapy.
  1992
• Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
  New England Journal of Medicine, 1990
• Clinical trials of WR-2721 and cis-platinum
  International Journal of Radiation Oncology*Biology*Physics, 1989
• UPTAKE OF WR-2721 DERIVATIVES BY CELLS IN CULTURE - IDENTIFICATION OF THE TRANSPORTED FORM OF THE DRUG
  1988
• Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)
  New England Journal of Medicine, 1983
• Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
  Annals of Internal Medicine, 1979
• EFFECT OF DOXORUBICIN ON HEPATIC AND CARDIAC GLUTATHIONE
  1979
• CONTROLLED CLINICAL STUDIES WITH AN ANTIDOTE AGAINST THE UROTOXICITY OF OXAZAPHOSPHORINES - PRELIMINARY-RESULTS
  1979
• Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation.
  1975
• Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943)
  Toxicology and Applied Pharmacology, 1974